RESUMO
Objective To explore the correlation difference between dynamic and routine electrocardiogram when used to diagnose asymptomatic myocardial ischemia.Methods Totally 92 coronary disease patients confirmed clinically from April 2014 to May 2016 were divided equally and randomly into an observation group and a control group.The patients in the control group underwent conventional ECG examination,and the ones in the observation group went through 24 h 12-lead dynamic ECG examination.The positive rates of asymptomatic myocardial ischemia were compared in the two groups,and the onset time and the patient state at that moment were analyzed in the observation group,Results The positive rates in the control group and observation group were 47.83％ and 84.78％ respectively,and there was significant difference between them (P＜0.05).The onset time was restrained within 6:00 and 12:00,when the patient was in the state of manual labor,brain work or excitement.Conclusion 24 h 12-lead dynamic ECG gains advantages in early and timely diagnosis of asymptomatic myocardial ischemia,and thus is worthy promoting clinically.
RESUMO
Objective:To observe the effect of epalrestat on the heart rate variability in diabetes patients with silent myocardial is-chemia. Methods:Totally 60 patients were randomly divided into the control group and the treatment group with 30 cases in each. The two groups were given insulin or other routine drugs to keep blood sugar under control, ARB or ACEI and CCB to bring high blood pres-sure down, and statins to regulate lipid and anti-platelet aggregation, and both groups were without the use of beta blockers. The treat-ment group was given epalrestat 50mg three times a day for 4 weeks additionally. The indices of FPG, 2hPG, HbA1c, SBP, DBP, T-CHOL, TG, HDL-C, LDL-C and heart rate variability were observed after the treatment. Results: Compared with those before the treatment, the values of FPG, 2HPG, HbA1C, SBP, DBP, T-CHOL and LDL-c were decreased after the treatment in the two groups, and the differences were statistically significant (P 0. 05). After the treatment, SDNN, SDANN, SDNNI, RMSSD, PNN50 and Mean HR in the treatment group were obviously im-proved, which were better than those in the control group (P<0.05). The adverse reactions in the two groups were similar (P<0. 05). Conclusion:Epalrestat can significantly improve HRV-related indicators in the diabetes patients with silent myocardial ischemi-a, which can reduce the risk of sudden death without significant adverse reactions in the combination with other drugs.